{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phaseb', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(+3 days)', '( 3 days)', '( 3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', '-', '-', '-', '-', 'Dispense IP', 'X', 'X', 'X', 'X', 'X', 'X', 'Return and Count IP', '-', '-', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'Tablets', 'Abbreviations: BMI = body mass index; BSA = body surface area;', 'DLQI = Dermatology Life Quality Index; EQ-5D = European Quality of Life 5-', 'Dimension; FCBP = females of childbearing potential; IP = investigational product; NAPSI = Nail Psoriasis Severity Index; PASI = Psoriasis Area Severity Index; PBQ = Patient', 'Benefit Questionnaire; PNQ = Patient Needs Questionnaire; PPPGA = Palmoplantar Psoriasis Physicians Global Assessment; NRS = Numeric Rating Scale; ScPGA = Scalp', 'Physician Global Assessment; sPGA = static Physicians Global Assessment; sPGA-G = static Physicians Global Assessment of Genitalia; VAS = Visual Analog Scale;', 'WPAI:PSO = Work Productivity and Activity Impairment Questionnaire: Psoriasis.', 'a Visits in the Placebo-controlled Phase to be performed 3 days.', 'b Visits in the Apremilast Extension Phase to be performed 4 days.', 'c Visit 9 will serve as the Early Termination Visit for any subject who prematurely discontinues from the study, prior to Week 52. All subjects who complete the study or', 'discontinue the study early will be asked to enter the Four-week Post-treatment Observational Follow-up Phase.', 'd', 'Post-treatment observational follow-up will be conducted by telephone.', 'e Written informed consent will be obtained by the Principal Investigator or designee prior to initiation of any study procedures, including washouts from prior medications.', 'f Adverse event review should include new or worsening psychiatric symptoms, suicidal ideation, suicidal attempt, severe diarrhea, nausea and vomiting, and unexplained and', 'clinically significant weight loss. See Section 6.5.', 'g Females of childbearing potential (FCBPs) only. Serum pregnancy tests are performed at Screening, and Early Termination Visit/Last Treatment Visit. Urine pregnancy test kit', 'will also be provided to the site and performed at baseline prior to randomization. The Investigator will educate all FCBP about the different options of contraceptive methods', 'and their correct use at Screening and Baseline visits. The subject will be reeducated every time their contraceptive measures/methods or their ability to become pregnant', 'changes. A pregnancy test(s) should be administered if the FCBP subject misses a menstrual period.', 'h', 'Laboratory assessments will include routine/standard chemistry and hematology panel of tests. A lipid panel will be included in the standard chemistry panel. If screening', 'laboratory assessments are within 7 days of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline (Week 0). For females of childbearing potential', 'urine pregnancy test will be performed at Baseline (Week 0) to confirm subject eligibility (negative results required for IP administration).', 'j Subject assessments must be completed in the following order: DLQI, Itch NRS, Skin Discomfort/Pain VAS, EQ-5D, PNQ/PBQ, and WPAI: PSO, as scheduled in the Table of', 'Events.', 'k All manifestations should be assessed in all subjects at all visits, so that improvement, worsening, or new onset of any of these manifestations can be assessed.', '1', 'Nail assessments will evaluate presence of nail psoriasis, defined as onycholysis and onychodystrophy.', 'm Photographs will be obtained from subjects who provide separate consent to be photographed and at select sites only.', 'Confidential and Proprietary', '31', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.', 'PROCEDURES', 'The following procedures will be conducted as outlined in the Table of Events, Table 3.', '6.1.', 'Screening Period', 'Screening evaluations will be performed for all subjects to determine study eligibility. These', 'evaluations must be completed within 5 weeks of randomization. Subjects who do not meet', 'eligibility criteria for the study may be re-screened once, after a minimum of 35 days from the', 'date of their first screening.', 'Waivers to the protocol will not be granted during the conduct of this trial, under any', 'circumstances.', 'Safety laboratory analyses and all assessments will be performed (locally/centrally). Screening', 'laboratory values must demonstrate subject eligibility, but may be repeated once within the', 'screening window, if necessary.', 'The following will be performed at screening as specified in the Table of Events, after informed', 'consent has been obtained:', 'Demographics (year of birth, sex, and race, if allowed by local regulations, will be', 'collected).', 'Complete medical history', 'Prior and concomitant medications', 'Physical examination, height, weight, waist circumference, body mass index (see', 'Appendix O)', 'Vital signs (including blood pressure and heart rate)', 'Hematology panel including complete blood count (CBC) with differential, including red', 'blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH),', 'mean corpuscular hemoglobin concentration (MCHC), RBC Morphology, mean', 'corpuscular volume (MCV), white blood cell (WBC) count (with differential), and', 'platelet count.', 'Chemistry panel including sodium, potassium, calcium, chloride, blood urea nitrogen', '(BUN), creatinine, creatinine clearance, glucose, albumin, total protein, alkaline', 'phosphatase, bilirubin (total and direct), aspartate aminotransferase/serum glutamic', 'oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic', 'transaminase (ALT/SGPT), gamma-glutamyl transferase (GGT), lactate dehydrogenase', '(LDH). A lipid panel will be included in the standard chemistry panel.', 'Pregnancy test is required for all female subjects of childbearing potential. Serum beta', 'human chorionic gonadotropin (B-hCG) pregnancy test will be performed at screening.', 'Urine (or serum) pregnancy test will be performed to assess subject eligibility within 72', 'Confidential and Proprietary', '32', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'hours prior to the first administration of IP, if the initial serum pregnancy test did not', 'already occur with 72 hours of dosing (negative results required for IP administration).', 'Contraception education will be performed by the Investigator at screening for all FCBP', 'about the options for and correct use of contraceptive methods at the Screening and', \"Baseline Visits and at any time when a FCBP's contraceptive measures or ability to\", 'become pregnant changes.', '-', 'A pregnancy test should be performed if the FCBP subject has missed a menstrual', 'period or the contraception method has changed', '- Counseling about pregnancy precautions and the potential risks of fetal exposure', 'must be conducted.', 'Adverse event assessment begins when the subject signs the informed consent form', 'Health-related quality of life and efficacy assessments to determine study eligibility,', 'including DLQI, sPGA of visible locations, ScPGA, NAPSI, modified sPGA-G, PPPGA,', 'and PASI', '6.2.', 'Treatment Period', 'The subject will begin treatment upon confirmation of eligibility. The subject must start', 'treatment within 35 days (5 weeks) of signing the ICF. An administrative window of 3 day is', 'permitted for Visits 3 and 4 and 4 days is permitted for Visits 5 through 9.', 'The following procedures will be conducted as outlined in the Table of Events, Table 3. The', 'evaluations should be performed prior to dosing on the visit day, unless otherwise specified.', 'Inclusion/Exclusion criteria (Baseline/Visit 2)', 'Concomitant medications and therapies evaluation', 'Vital signs', 'Weight, waist circumference', 'Adverse event evaluation (continuously and through 28 days after last dose of', 'apremilast)', 'Clinical laboratory evaluations [If screening laboratory assessments are within 7 days', 'of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline', '(Week 0)]', 'Efficacy assessment (see Section 6.4) [In addition to assessments specified in Table 3,', 'investigator will follow country guidelines to monitor therapy outcomes according to', 'clinical routine care and may assess efficacy or safety at any unscheduled visit and', 'document in source documents.]', 'Dispense IP', 'Return and count IP tablets', 'Urine (or serum) pregnancy test (prior to dosing on Day 1)', 'Confidential and Proprietary', '33', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}